Compare Mesoblast Limited (MESO) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Prudential Financial Inc — how do they compare? Mesoblast Limited trades at $17.32 (market cap $2.18B), while Prudential Financial Inc trades at $119.04 (market cap $41.36B). The key difference: Prudential Financial Inc is far larger — about 19× Mesoblast Limited's market cap, and Prudential Financial Inc pays a 4.7% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | PRU | |
|---|---|---|
Market Cap | $2.18B | $41.36B |
Sector | Technology | Financials |
52-Week High | $20.96 | $119.07 |
52-Week Low | $12.88 | $92.00 |
Enterprise Value | $2.18B | $68.41B |
Dividend Yield | — | 4.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mesoblast (MESO) trades at $17.32, down 3.02% on the day, with a bullish technical signal from moving averages and strong analyst support (45% buy rating). The company shows significant revenue growth with Ryoncil generating $115M annually, but remains unprofitable with a -144% net income margin. Recent milestones include completing patient recruitment for a pivotal Phase 3 trial and securing a $50M non-dilutive facility.
The investment thesis centers on Mesoblast's transition to a commercial-stage company with FDA-approved Ryoncil and promising pipeline assets. Key opportunities include potential label expansions and regulatory approvals, while risks involve continued cash burn, clinical trial outcomes, and achieving sustained profitability. The stock's high P/S ratio of 30.5 reflects growth expectations rather than current earnings.
Prudential Financial (PRU) trades at $119.07, up 0.69% on the day, with a bullish technical outlook supported by moving averages and strong support at $117. Fundamentally, the company shows solid profitability with a net income margin of 5.5% and ROE of 11.08%, while trading at a discount with a P/E of 12.26 and P/S of 0.67. Recent earnings beat expectations in Q1 2026, and a $1.40 dividend was declared for H1 2026, reflecting shareholder returns.
The stock presents a mixed outlook: analyst consensus is cautious with 67.57% hold ratings and a price target of $102.50, below the current price, indicating potential overvaluation. Risks include volatile cash flows and high debt levels, but growth in retirement services and international expansion offer long-term opportunities. Investors should weigh solid fundamentals against cautious Wall Street sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
